REVIEW Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent, which improves myocardial glucose utilization through inhibition of fatty acid metabolism, also known as fatty acid oxidation inhibitor. By preserving the energy metabolism in cells exposed to hypoxia or ischemia, trimetazidine prevents a decrease in intracellular adenosine triphosphate levels, thereby ensuring the proper functioning of ionic pumps and transmembranous sodium-potassium flow whilst maintaining cellular homeostasis. It also inhibits oxidation of fatty acid in blood vessels.
Masmoudi K, Masson H, Gras V, Andréjak M (2012). Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundam Clin Pharmacol. 26(2):198-203. PMID 22044594.
Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, Ge J (2012). Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 59(10):913-22. PMID 22381427.